Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
Research Watch

Glutaminolysis Drives Lung Cancer Metastasis via the PLAG1–GDH1 Axis

DOI: 10.1158/2159-8290.CD-RW2018-004
  • Article
  • Info & Metrics
Loading
  • Major finding: PLAG1-mediated GDH1 upregulation promotes LKB1-deficient lung cancer anoikis resistance.

  • Mechanism: In the absence of LKB1, the GDH1 product α-KG mediates the activation of AMPK by CAMKK2.

  • Impact: Targeting the PLAG1–GDH1 axis may be a potential therapeutic strategy to prevent metastasis.


Embedded Image

Loss of liver kinase B1 (LKB1, encoded by STK11), which regulates the activation of the metabolic regulator AMPK, is associated with increased metastasis and decreased survival in patients with lung cancer. To elucidate the mechanism underlying the prometastatic role of altered tumor metabolism in lung cancer, Jin and colleagues interrogated the glutaminolysis pathway, which promotes tumor growth and metastasis. The glutaminolytic enzyme glutamate dehydrogenase 1 (GDH1) was shown to confer anoikis resistance, which is required for metastasis, in LKB1-deficient lung cancer cell lines. The transcription factor pleomorphic adenoma gene 1 (PLAG1) was upregulated during anoikis resistance and transactivated the GDH1 promoter; PLAG1 knockdown decreased GDH1 expression and increased anoikis. Knockdown of GDH1 sensitized LKB1-deficient, but not LKB1-proficient, cells to anoikis induction in vitro and reduced the metastatic potential of LKB1-deficient cells in vivo, whereas the GDH1 product α-KG restored anoikis resistance in GDH1-depleted LKB1-deficient cells, suggesting that both GDH1 and α-KG promote anoikis resistance. Similarly, treatment of LKB1-null cells with a small-molecule inhibitor of GDH1 rescued anoikis in vitro and attenuated the metastatic potential of LKB1-deficient cell lines and patient-derived xenografts in vivo. Further, GDH1 knockdown resulted in decreased activation of AMPK and its upstream activator calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2), which were rescued by the addition of α-KG, and diminished cellular ATP levels. CAMKK2 knockdown resulted in the loss of AMPK activation and anoikis resistance in LKB1-deficient cells; conversely, CAMKK2 overexpression restored anoikis resistance and AMPK activation in GDH1-knockdown cells. Mechanistically, α-KG promoted CAMKK2 activation by enhancing the interaction between CAMKK2 and its substrate AMPKα. Consistent with these findings, GDH1 signaling was correlated with metastasis in human LKB1-deficient lung cancers. These results describe the mechanism by which glutaminolysis promotes metastasis and suggest that GDH1 may be a potential antimetastatic target.

Jin L, Chun J, Pan C, Kumar A, Zhang G, Ha Y, et al. The PLAG1-GDH1 axis promotes anoikis resistance and tumor metastasis through CamKK2-AMPK signaling in LKB1-deficient lung cancer. Mol Cell 2017 Dec 14 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2018 American Association for Cancer Research.
View Abstract
Next
Back to top

Published OnlineFirst January 5, 2018
doi: 10.1158/2159-8290.CD-RW2018-004

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Glutaminolysis Drives Lung Cancer Metastasis via the PLAG1–GDH1 Axis
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
Citation Tools
Glutaminolysis Drives Lung Cancer Metastasis via the PLAG1–GDH1 Axis
Cancer Discov January 5 2018 DOI: 10.1158/2159-8290.CD-RW2018-004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Glutaminolysis Drives Lung Cancer Metastasis via the PLAG1–GDH1 Axis
Cancer Discov January 5 2018 DOI: 10.1158/2159-8290.CD-RW2018-004
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The EZH2 Inhibitor Tazemetostat Is Well Tolerated in a Phase I Trial
  • Dual Targeting of MDMX and MDM2 Has Antileukemic Activity
  • A Cancer-Germline Antigen Signature Predicts Anti-CTLA4 Resistance
Show more Research Watch
  • Home
  • Alerts
  • Feedback
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement